Severe Cardiovascular Complications of COVID-19: a Challenge for the Physician
AUTOR(ES)
Crivelari, Nathalie Cristina; Oliveira, Gisele Queiroz de; Park, Clarice Hyesuk Lee; Riemma, Gregorio da Cruz; Costa, Isabela Bispo Santos da Silva; Lacerda, Marcus Vinícius Guimarães de; Oliveira, Glaucia Maria Moraes de; Darrieux, Francisco Carlos da Costa; Sacilotto, Luciana; Hajjar, Ludhmila Abrahão
FONTE
Int. J. Cardiovasc. Sci.
DATA DE PUBLICAÇÃO
2020-10
RESUMO
Abstract Background: Vitiligo is a common skin disorder in which melanocytes are destroyed by auto-reactive immune responses. The loss of melanocytes results in the appearance of depigmented areas in different parts of the body. Cytokines have remarkable roles in the pathogenesis of vitiligo, such as IL-1, IL-6, and TNF-α; interleukin 27 (IL-27) is a new member of the IL-6/IL-12 family, mainly released by activated antigen-presenting cells. IL-27 has been suggested to function as a pro-inflammatory as well as an anti-inflammatory cytokine. Altered concentrations of IL-27 have been shown in various auto-immune diseases such as multiple sclerosis, rheumatoid arthritis, and psoriasis. No studies have been conducted to determine the expression of this cytokine in vitiligo patients. Objective: The objective of this study was to determine the serum concentration of IL-27 in vitiligo patients and compare it with normal individuals. Methods: The serum concentration of IL-27 in 79 vitiligo patients was evaluated in comparison to 45 healthy controls using ELISA assay. Results: Results showed decreased concentration of IL-27 in vitiligo patients as compared with healthy subjects (p = 0.026). Furthermore, no correlation between IL-27 concentrations and disease parameters such as vitiligo severity and the extension of the depigmented area was observed. Study limitation: A larger sample size would be more recommended for this study. Conclusion: The reduction in the serum levels of IL-27 in vitiligo patients compared to normal subjects suggested the possible anti-inflammatory role of this cytokine in vitiligo. Thus, IL-27 may be considered as a new target for the manipulation of the immune system in vitiligo patients.
Documentos Relacionados
- Dementia and COVID-19: complications of managing a pandemic during another pandemic
- Cardiovascular involvement in COVID-19: not to be missed
- Ultrasound findings in severe COVID-19: a deeper look through the carotid arteries
- COVID-19: GENERAL GUIDELINES FOR CARDIOVASCULAR SURGEONS (standard guidelines - subject to change)
- Vascular Spectrum of Imaging Findings in COVID-19: Ischemic, Hemorrhagic, and Thromboembolic Complications